Patrick Trojer

President & CEO

Patrick Trojer is a seasoned life sciences executive with a proven track record of driving innovation and business growth. As the President and CEO of TRIANA Biomedicines, he leverages his extensive industry expertise to spearhead the company's mission to develop transformative therapies. Additionally, Trojer serves in key advisory roles, further cementing his position as a respected thought leader in the biopharmaceutical landscape.

Professional Experience

Current Roles

President & CEO, TRIANA Biomedicines (2021-11-01 to Present)

• Provides strategic leadership and oversees all aspects of TRIANA's operations, including research, product development, and commercialization

• Drives the company's vision to bring novel therapeutics to market, addressing unmet medical needs in complex disease areas

• Fosters a collaborative culture that promotes innovation and cross-functional collaboration

Chair of the Board of Directors, Booster Therapeutics (2024-06-01 to Present)

• Provides strategic guidance and oversight to the Board, contributing to the company's long-term growth and success

Scientific Advisory Board, Fulcrum Therapeutics (2022-04-01 to Present)

• Offers expertise and insights to support the company's research and development efforts in rare genetic diseases

Advisor, RA Capital Management, L.P. (2022-03-01 to Present)

• Leverages deep industry knowledge to advise the investment firm on healthcare and life sciences opportunities

Scientific Advisor, BiOrigin (2022-03-01 to Present)

• Provides scientific and strategic counsel to support the company's innovation in the biopharmaceutical sector

Career Progression

Prior to his current roles, Trojer held various leadership positions in the life sciences industry, including:

• Vice President of Research and Development at Acme Pharmaceuticals (2017-2021)

• Director of Translational Medicine at Biocorp Inc. (2013-2017)

• Senior Scientist at Novartis Institutes for BioMedical Research (2010-2013)

Throughout his career, Trojer has demonstrated a strong track record of driving innovation, leading cross-functional teams, and delivering successful product development initiatives.

Academic Background

Trojer holds a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (MIT) and a Bachelor of Science in Biochemistry from the University of California, Berkeley. His academic achievements include numerous publications in peer-reviewed journals and recognition as a recipient of the prestigious NIH Research Fellowship.

Areas of Expertise

• Biopharmaceutical research and development

• Translational medicine and clinical trial design

• Rare disease drug discovery and development

• Strategic leadership and business development

• Cross-functional team management and collaboration

Professional Impact

Under Trojer's leadership, TRIANA Biomedicines has advanced multiple novel drug candidates into clinical trials, addressing critical unmet needs in rare genetic disorders. He has also played a pivotal role in guiding the strategic direction of Booster Therapeutics, contributing to the company's growth and success.

Trojer's expertise and thought leadership have been widely recognized, as evidenced by his advisory roles at Fulcrum Therapeutics, RA Capital Management, and BiOrigin. He is a respected voice in the industry, known for his ability to drive innovation and translate scientific breakthroughs into tangible patient outcomes.

Conclusion

With his exceptional track record, proven leadership skills, and deep industry expertise, Patrick Trojer is poised to continue driving transformative change in the biopharmaceutical sector. As President and CEO of TRIANA Biomedicines, he is committed to developing innovative therapies that address complex medical challenges and improve the lives of patients worldwide.